A Summary of the First 6 HLA-B8+ Persons in Which DCs Were Pulsed With EBNA-3A Peptide, Added at a Dose of 1:5 to 1:60 to T Cells, Without or With Supplemental IL-2
| Experiment No. . | E:T Ratio . | DC:T Ratio . | % Specific Lysis . | |||
|---|---|---|---|---|---|---|
| Without IL-2 . | With IL-2 . | |||||
| B8+ LCL, No Peptide . | B8+LCL+ FLRGRAYGL Peptide . | B8+ LCL, No Peptide . | B8+ LCL+ FLRGRAYGL Peptide . | |||
| 1 | 10:1 | 1:5 | 0 | 41 | NT | NT |
| 20:1 | 1:5 | 0 | 75 | NT | NT | |
| 2 | 10:1 | 1:10 | 0 | 90 | 0 | 96 |
| 1:30 | 0 | 76 | 5 | 96 | ||
| 3 | 20:1 | 1:38 | 7 | 31 | NT | NT |
| 4 | 20:1 | 1:30 | 0 | 12 | 5 | 22 |
| 5 | 20:1 | 1:60 | 0 | 11 | 5 | 23 |
| 6 | 10:1 | 1:60 | NT | NT | 4 | 60 |
| 20:1 | 1:60 | 5 | 68 | 19 | 71 | |
| Experiment No. . | E:T Ratio . | DC:T Ratio . | % Specific Lysis . | |||
|---|---|---|---|---|---|---|
| Without IL-2 . | With IL-2 . | |||||
| B8+ LCL, No Peptide . | B8+LCL+ FLRGRAYGL Peptide . | B8+ LCL, No Peptide . | B8+ LCL+ FLRGRAYGL Peptide . | |||
| 1 | 10:1 | 1:5 | 0 | 41 | NT | NT |
| 20:1 | 1:5 | 0 | 75 | NT | NT | |
| 2 | 10:1 | 1:10 | 0 | 90 | 0 | 96 |
| 1:30 | 0 | 76 | 5 | 96 | ||
| 3 | 20:1 | 1:38 | 7 | 31 | NT | NT |
| 4 | 20:1 | 1:30 | 0 | 12 | 5 | 22 |
| 5 | 20:1 | 1:60 | 0 | 11 | 5 | 23 |
| 6 | 10:1 | 1:60 | NT | NT | 4 | 60 |
| 20:1 | 1:60 | 5 | 68 | 19 | 71 | |
Seven days later, CTLs were measured on B8+ LCLs to which EBNA-3A peptide was or was not added. The left-hand column is the T cell (E):target cell (T) ratio for CTL assay.
Abbreviation: NT, not tested.